TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31347002
Drug: Triple puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple puncture treatment (6 times per week for 4 weeks)
Study: 31347002
Drug: Carbamazepine (300‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (300‐600 mg per day for at least 1 month)
Study: 29566104
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus Letrozole (10 mg/d + 2.5 mg/d) in first-line treatment
Study: 29566104
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus Exemestane (10 mg/d + 25 mg/d) in second-line treatment
Study: 29566104
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in first-line treatment
Study: 29566104
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in second-line treatment
Study: 22555350
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral care protocol (tongue scraping, electric toothbrushing, moisturizing)
Study: 22555350
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care protocol (manual toothbrushing)
Study: 20681276
Drug: Gingko biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gingko biloba Tablet (GBT)
Study: 16275189
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (50 to 70 mug/kg/min)
Study: 10500058
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg once daily)
Study: 8953672
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g bolus dose)
Study: 8953672
Drug: Lymecycline (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline (10-day course of 300 mg twice daily)
Study: 1834805
Drug: Fibrinolysis and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis and aspirin combined
Study: 7046098
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg daily
Study: 25986943
Drug: 10-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day quadruple anti-H. pylori treatment with a single dosage of omeprazole and bismuth
Study: 25986943
Drug: Lookalike placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lookalike placebos with a single dosage of omeprazole and bismuth
Study: 20586002
Drug: 3.75 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 microg antigen with 50% of the standard MF59 dose (group A)
Study: 20586002
Drug: 7.5 microg
Normalized name: Levonorgestrel 37.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 microg antigen and 100% standard MF59 dose (group B)
Study: 17354223
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) administration of yttrium‐90‐labeled murine monoclonal antibody HMFG1 ((90)Y‐muHMFG1)
Study: 15689218
Drug: 5% Dead
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Dead Sea salt solution (Mavena(R) Dermaline Mg(46) Dead Sea salt) for 15 minutes
Study: 15689218
Drug: 5% Dead
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Dead Sea salt solution
Study: 12196422
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nateglinide and troglitazone
Study: 8129216
Drug: Double-blind, placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind, placebo-controlled oral challenge test
Study: 2774259
Drug: liquids, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquids, up to 5 ml/kg + placebo (glucose water 0.2 ml/kg)
Study: 2774259
Drug: liquids, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquids, up to 5 ml/kg + ranitidine 2 mg/kg in glucose water 0.2 ml/kg
Study: 16710349
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g cholestyramine
Study: 3373260
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of weekly fluorouracil (5-FU) at a dose of 750 mg/m2 incrementally increased to 3,400 mg/m2
Study: 3373260
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of weekly fluorouracil (5-FU) plus N-(phosphonacetyl)-L-aspartic acid (PALA) administered as an IV bolus over 15 minutes at a fixed dose of 250 mg/m2
Study: 30912860
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Monitor-Only (MO)
Study: 19690066
Drug: rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 8 mg daily for 16 weeks
Study: 11585270
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Ondansetron 8 mg i.v. at 4-h intervals plus dexamethasone 20 mg i.v. from the start of CT, followed by dexamethasone 5 mg i.v. every 12 h until CT was complete.
Study: 11585270
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Same treatment as arm A but with ondansetron 8 mg i.v. given at 24-h intervals.
Study: 6500902
Drug: Bornaprine 8
Normalized name: bornaprine
DrugBank: Bornaprine (DB13619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprine 8 mg daily
Study: 6500902
Drug: Bornaprine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprine (various rising doses)
Study: 31413233
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of Hericium erinaceus for 12 weeks
Study: 30589045
Drug: OxyContin 10
Normalized name: OxyContin 10mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin 10 mg orally, adjusted according to pain relief
Study: 19136369
Drug: Golimumab (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (50, 100, or 200 mg)
Study: 11424316
Drug: Clarithromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 5 days
Study: 11424316
Drug: Clarithromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 7 days
Study: 9663361
Drug: 2% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide administered topically TID
Study: 9663361
Drug: 0.5% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% betaxolol administered topically BID plus placebo administered topically QD
Study: 959332
Drug: Bronchodilator and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator and bronchial drainage
Study: 959332
Drug: Bronchodilator/mucolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator/mucolytic agents and bronchial drainage
Study: 959332
Drug: Mucolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytic agent with bronchial drainage
Study: 959332
Drug: Comparison among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison among three treatments
Study: 31002537
Drug: GP2017 (adalimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2017 (adalimumab biosimilar) 40 mg subcutaneous injection
Study: 25406528
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg kg‐1 day‐1 (placebo)
Study: 25406528
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg‐1 day‐1
Study: 25406528
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg kg‐1 day‐1
Study: 23004236
Drug: All fit
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All fit SSO implants
Study: 23004236
Drug: SPI contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI contact implants
Study: 23004236
Drug: SPI element
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI element implants
Study: 19672180
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice group (BIS recorded but not guiding drug administration)
Study: 10735015
Drug: Treatment comparable
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment comparable to white women
Study: 9311629
Drug: Ritonavir with
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir with fluconazole (400 mg on day 1, 200 mg every day on days 2-5)
Study: 9311629
Drug: Ritonavir alone
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir alone (200 mg every 6 hr for 4 days)
Study: 24162762
Drug: Intra‐articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular hyaluronic acid injections (2 cycles of 5 weekly injections at 6-month intervals) after high tibial osteotomy (HTO)
Study: 24162762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intra‐articular injections after HTO)
Study: 24162762
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (intra‐articular hyaluronic acid injections)
Study: 22430450
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control with insulin (target BGC 4‐6 mmol/L)
Study: 22430450
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice (restrictive guidelines for starting insulin, target BGC 8‐10 mmol/L)
Study: 1859906
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen therapy
Study: 11954868
Drug: IFNbeta‐1 b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1 b combined with monthly intravenous methylprednisolone (MP)
Study: 11954868
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFNbeta‐1 b + MP)
Study: 10375338
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogesterone, 2.5 mg/d
Study: 6775954
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg chenodeoxycholic acid (4 X 125 mg gelatin‐coated capsules)
Study: 6775954
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg chenodeoxycholic acid
Study: 6775954
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg chenodeoxycholic acid
Study: 6775954
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg chenodeoxycholic acid
Study: 30307514
Drug: Medium cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium cut-off dialyzers (with extended middle molecule removal) during hemodialysis
Study: 26087610
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night
Study: 23351813
Drug: Partial oral
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial oral treatment with antibiotics after a minimum of 10 days of parenteral treatment.
Study: 23351813
Drug: Full parenteral
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full parenteral treatment (unchanged parenteral therapy).
Study: 17593859
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (10 microg/kg) plus IV PCA morphine
Study: 17593859
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA morphine alone
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + MET (dual therapy)
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + TGZ (dual therapy)
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + MET, add TGZ (triple therapy)
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + TGZ, add MET (triple therapy)
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + TGZ add MET (triple therapy)
Study: 15220231
Drug: INS +
Normalized name: Eye Vitamins + Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS + MET add TGZ (triple therapy)
Study: 2679483
Drug: Adjunctive amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive amitriptyline hydrochloride
Study: 2679483
Drug: Adjunctive desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive desipramine hydrochloride
Study: 168120
Drug: Chloroquine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (500 mg daily for 10 weeks)
Study: 168120
Drug: Metronidazole (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (750 mg three times daily for 10 days)
Study: 31166383
Drug: Lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective ventilation (PV group) with 7 mL/kg tidal volume and personal level of PEEP
Study: 31166383
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (CV group) with 10 mL/kg tidal volume without PEEP
Study: 23204161
Drug: Specific ART
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific ART medications (e.g., atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir, lopinavir/ritonavir)
Study: 21421658
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (200 mg, single oral dose)
Study: 21421658
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg, o.d.) and Vitamin C (150 mg, o.d.)
Study: 1732771
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management of labor (amniotomy within one hour of diagnosis, oxytocin infusion starting at 6 mU/min, increasing to a maximum of 36 mU/min)
Study: 6431939
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment
Study: 22154650
Drug: Ifosfamide/actinomycin/vincristine-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide/actinomycin/vincristine-based chemotherapy with local therapy (radiotherapy or surgery)
Study: 19924786
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local therapy
Study: 12569115
Drug: Bifidobacteria-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria-fermented milk (BFM), 100 mL/day for one year
Study: 9316009
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (CBDCA) 400 mg/m2 on day 1 and oral etoposide 50 mg/m2 on days 1-21 (Group I)
Study: 9316009
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide 50 mg/m2 on days 1-21 alone (Group II)
Study: 9316009
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (CBDCA) with etoposide (Group I)
Study: 9316009
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide alone (Group II)
Study: 3875515
Drug: Cetacaine spray
DrugBank: Butamben (DB11148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetacaine spray
Study: 3875515
Drug: Hurricaine spray
Normalized name: Hurricaine Spray Extension Tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hurricaine spray
Study: 3875515
Drug: 10% Xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Xylocaine spray
Study: 29971997
Drug: Auricular intradermal
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular intradermal needling combined with erjian (HX6,7i) bloodletting
Study: 29971997
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of estazolam (1mg each day for 4 weeks)
Study: 24070810
Drug: Cold compress
Normalized name: RITE AID Hot & Cold Compress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold compress (CC)
Study: 24070810
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears combined with cold compress (ATs + CC)
Study: 24070810
Drug: Cold compress
Normalized name: RITE AID Hot & Cold Compress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold compress combined with artificial tears (CC + ATs)
Study: 24070810
Drug: Cold compress
Normalized name: RITE AID Hot & Cold Compress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold compress combined with epinastine hydrochloride (CC + EH)
Study: 24070810
Drug: Epinastine hydrochloride
Normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine hydrochloride combined with cold compress (EH + CC)
Study: 22975501
Drug: OHA 2
Normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHA 2 mg, 4 mg, and 8 mg (single and multiple doses)
Study: 22975501
Drug: OHA 4
Normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHA 4 mg (fed condition)
Study: 22975501
Drug: OHA (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHA (single-dose and multiple-dose) in elderly
Study: 10553738
Drug: Clozapine 600
Normalized name: clozapine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 600 mg/day
Study: 15951089
Drug: Clozapine with
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine with plasma levels > 150 ng/ml
Study: 15951089
Drug: Clozapine regardless
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine regardless of dose
Study: 10066007
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose clomipramine
Study: 10066007
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose clomipramine
Study: 24969712
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy with HFCWO
Study: 17405901
Drug: FOLFOX4 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 plus bevacizumab (10 mg/kg, i.v. infusion on day 1, every 2 weeks)
Study: 10453433
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (187 patients) with systematic lipid assessment and active pharmacologic lipid therapy.
Study: 2675597
Drug: Strict diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict diabetic protocol (diet and insulin therapy)
Study: 2675597
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal oral glucose tolerance test)
Study: 322251
Drug: Dissolvent tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolvent tablets containing mixed enzyme preparations
Study: 322251
Drug: Dissolvent tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolvent tablets containing pure enzymes
Study: 322251
Drug: Steradent tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steradent tablets
Study: 29268061
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion
Study: 23637967
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg CPG 7909 as adjuvant
Study: 21991704
Drug: Cooled lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled lignocaine gel (4 degrees C)
Study: 21991704
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature lignocaine gel (20 degrees C)
Study: 10562823
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg body weight over 3 days) + Primaquine (15 mg daily for 14 days)
Study: 1686131
Drug: Flumazenil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.5 mg/h
Study: 1686131
Drug: Flumazenil 0.1
Normalized name: flumazenil 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.1 mg/h
Study: 25295719
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with morphine (M group)
Study: 25295719
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with tramadol combined with lornoxicam (L group)
Study: 22777991
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (80 mg of elemental iron daily)
Study: 17563739
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 2 (IL-2) at 1 million units/m² SQ daily for 28 days